- Home
- AMIX vs MTEM Comparison
AMIX vs MTEM Comparison
Compare AMIX & MTEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMIX
- MTEM
- Stock Information
- Founded
- AMIX 2014
- MTEM 2001
- Country
- AMIX United States
- MTEM United States
- Employees
- AMIX N/A
- MTEM N/A
- Industry
- AMIX
- MTEM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMIX
- MTEM Health Care
- Exchange
- AMIX NYSE
- MTEM Nasdaq
- Market Cap
- AMIX 8.9M
- MTEM 9.7M
- IPO Year
- AMIX N/A
- MTEM N/A
- Fundamental
- Price
- AMIX $6.24
- MTEM $0.40
- Analyst Decision
- AMIX
- MTEM
- Analyst Count
- AMIX 0
- MTEM 0
- Target Price
- AMIX N/A
- MTEM N/A
- AVG Volume (30 Days)
- AMIX 1.5M
- MTEM 17.8M
- Earning Date
- AMIX 11-11-2024
- MTEM 11-26-2024
- Dividend Yield
- AMIX N/A
- MTEM N/A
- EPS Growth
- AMIX N/A
- MTEM N/A
- EPS
- AMIX N/A
- MTEM N/A
- Revenue
- AMIX N/A
- MTEM $25,470,000.00
- Revenue This Year
- AMIX N/A
- MTEM N/A
- Revenue Next Year
- AMIX N/A
- MTEM N/A
- P/E Ratio
- AMIX N/A
- MTEM N/A
- Revenue Growth
- AMIX N/A
- MTEM N/A
- 52 Week Low
- AMIX $7.51
- MTEM $0.30
- 52 Week High
- AMIX $152.00
- MTEM $5.37
- Technical
- Relative Strength Index (RSI)
- AMIX 57.64
- MTEM 38.94
- Support Level
- AMIX $11.70
- MTEM $0.32
- Resistance Level
- AMIX $13.78
- MTEM $0.62
- Average True Range (ATR)
- AMIX 1.70
- MTEM 0.11
- MACD
- AMIX 0.34
- MTEM 0.03
- Stochastic Oscillator
- AMIX 75.21
- MTEM 7.41
About AMIX AUTONOMIX MEDICAL INC
Autonomix Medical Inc is a development-stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its first-in-class technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies.
About MTEM Molecular Templates Inc.
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.